Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neisseria gonorrhoeae | 15 | 2025 | 199 | 3.730 |
Why?
|
| Gonorrhea | 12 | 2025 | 157 | 3.150 |
Why?
|
| Complement Factor H | 21 | 2025 | 118 | 3.040 |
Why?
|
| Immunoglobulin Fc Fragments | 8 | 2020 | 41 | 2.440 |
Why?
|
| Recombinant Fusion Proteins | 9 | 2022 | 489 | 1.680 |
Why?
|
| Immunotherapy | 5 | 2020 | 255 | 1.550 |
Why?
|
| Immunoglobulin G | 10 | 2024 | 459 | 1.120 |
Why?
|
| Complement Activation | 4 | 2022 | 47 | 1.080 |
Why?
|
| Bacterial Proteins | 9 | 2023 | 766 | 1.020 |
Why?
|
| Antigens, Bacterial | 13 | 2023 | 199 | 0.970 |
Why?
|
| Bacterial Infections | 2 | 2022 | 149 | 0.820 |
Why?
|
| N-Acetylneuraminic Acid | 3 | 2025 | 48 | 0.800 |
Why?
|
| Complement Pathway, Alternative | 1 | 2022 | 21 | 0.790 |
Why?
|
| Drug Resistance, Multiple | 2 | 2020 | 32 | 0.710 |
Why?
|
| Plants, Genetically Modified | 1 | 2020 | 22 | 0.690 |
Why?
|
| Bacterial Vaccines | 4 | 2023 | 78 | 0.650 |
Why?
|
| Porins | 5 | 2019 | 62 | 0.630 |
Why?
|
| Neisseria meningitidis | 6 | 2014 | 78 | 0.630 |
Why?
|
| Immune Evasion | 2 | 2025 | 68 | 0.630 |
Why?
|
| Complement System Proteins | 6 | 2022 | 105 | 0.620 |
Why?
|
| Lipopolysaccharides | 6 | 2025 | 625 | 0.560 |
Why?
|
| Anti-Bacterial Agents | 5 | 2024 | 784 | 0.540 |
Why?
|
| Meningococcal Infections | 2 | 2014 | 21 | 0.540 |
Why?
|
| Mice | 20 | 2025 | 10827 | 0.480 |
Why?
|
| Neisseria meningitidis, Serogroup C | 1 | 2014 | 4 | 0.450 |
Why?
|
| Animals | 26 | 2025 | 20631 | 0.430 |
Why?
|
| Streptococcus pyogenes | 3 | 2018 | 31 | 0.400 |
Why?
|
| Sialic Acids | 3 | 2025 | 33 | 0.400 |
Why?
|
| Meningococcal Vaccines | 4 | 2014 | 22 | 0.380 |
Why?
|
| Disease Models, Animal | 6 | 2023 | 2180 | 0.330 |
Why?
|
| Complement C3b | 2 | 2022 | 18 | 0.310 |
Why?
|
| Mice, Inbred BALB C | 8 | 2019 | 881 | 0.310 |
Why?
|
| Streptococcal Infections | 3 | 2018 | 80 | 0.290 |
Why?
|
| Humans | 25 | 2025 | 63292 | 0.270 |
Why?
|
| Protein Binding | 8 | 2018 | 1602 | 0.250 |
Why?
|
| Complement Inactivating Agents | 3 | 2018 | 14 | 0.240 |
Why?
|
| Complement C4b-Binding Protein | 3 | 2019 | 28 | 0.240 |
Why?
|
| Antibodies, Bacterial | 5 | 2023 | 181 | 0.230 |
Why?
|
| Interferons | 1 | 2025 | 73 | 0.230 |
Why?
|
| Retina | 1 | 2025 | 124 | 0.220 |
Why?
|
| Receptors, Fc | 1 | 2024 | 24 | 0.220 |
Why?
|
| Amino Acid Substitution | 4 | 2014 | 240 | 0.210 |
Why?
|
| Chagas Disease | 1 | 2024 | 36 | 0.210 |
Why?
|
| Trypanosoma cruzi | 1 | 2024 | 52 | 0.210 |
Why?
|
| Interferon Type I | 1 | 2025 | 187 | 0.210 |
Why?
|
| Properdin | 1 | 2022 | 12 | 0.200 |
Why?
|
| Virulence | 3 | 2018 | 193 | 0.190 |
Why?
|
| Macular Degeneration | 1 | 2025 | 187 | 0.190 |
Why?
|
| Bacterial Outer Membrane Proteins | 4 | 2018 | 121 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 178 | 0.170 |
Why?
|
| Female | 14 | 2025 | 32787 | 0.170 |
Why?
|
| Mice, Transgenic | 6 | 2024 | 1276 | 0.170 |
Why?
|
| Virulence Factors | 2 | 2018 | 84 | 0.170 |
Why?
|
| Blood Bactericidal Activity | 2 | 2011 | 62 | 0.160 |
Why?
|
| Binding Sites | 3 | 2016 | 903 | 0.160 |
Why?
|
| Immunoglobulin M | 1 | 2019 | 115 | 0.160 |
Why?
|
| Histocompatibility Antigens | 1 | 2019 | 106 | 0.160 |
Why?
|
| Global Burden of Disease | 1 | 2019 | 13 | 0.150 |
Why?
|
| Fimbriae, Bacterial | 1 | 2019 | 19 | 0.150 |
Why?
|
| Peptides | 2 | 2019 | 574 | 0.150 |
Why?
|
| Complement Inactivator Proteins | 1 | 2008 | 8 | 0.140 |
Why?
|
| Complement Pathway, Classical | 1 | 2008 | 17 | 0.140 |
Why?
|
| Staphylococcal Vaccines | 1 | 2017 | 2 | 0.140 |
Why?
|
| Haemophilus influenzae | 1 | 2016 | 26 | 0.130 |
Why?
|
| Haemophilus Infections | 1 | 2016 | 13 | 0.130 |
Why?
|
| Pan troglodytes | 2 | 2011 | 32 | 0.130 |
Why?
|
| Drug Design | 1 | 2016 | 135 | 0.120 |
Why?
|
| Species Specificity | 2 | 2011 | 334 | 0.120 |
Why?
|
| Immunologic Factors | 1 | 2016 | 105 | 0.120 |
Why?
|
| Incidence | 1 | 2019 | 1375 | 0.110 |
Why?
|
| Blood | 1 | 2014 | 30 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 4 | 2024 | 863 | 0.110 |
Why?
|
| Colony Count, Microbial | 1 | 2014 | 59 | 0.110 |
Why?
|
| Microbial Viability | 1 | 2014 | 55 | 0.110 |
Why?
|
| Rats, Wistar | 1 | 2014 | 185 | 0.110 |
Why?
|
| Epitopes | 3 | 2019 | 289 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2016 | 661 | 0.110 |
Why?
|
| Complement C3-C5 Convertases, Alternative Pathway | 1 | 2013 | 3 | 0.110 |
Why?
|
| Meningitis, Meningococcal | 1 | 2013 | 8 | 0.110 |
Why?
|
| Sepsis | 1 | 2017 | 286 | 0.110 |
Why?
|
| Protein Structure, Tertiary | 2 | 2014 | 671 | 0.100 |
Why?
|
| Neoplasms | 1 | 2024 | 1359 | 0.100 |
Why?
|
| Bacteria | 1 | 2016 | 304 | 0.100 |
Why?
|
| Bacteremia | 1 | 2011 | 94 | 0.090 |
Why?
|
| Vagina | 2 | 2023 | 83 | 0.080 |
Why?
|
| Arginine | 1 | 2011 | 124 | 0.080 |
Why?
|
| Heparin | 1 | 2011 | 116 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2025 | 3391 | 0.080 |
Why?
|
| Protein Interaction Mapping | 1 | 2009 | 68 | 0.070 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2009 | 247 | 0.070 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 1592 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1990 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2011 | 1148 | 0.070 |
Why?
|
| Phagocytosis | 2 | 2018 | 264 | 0.060 |
Why?
|
| Cathelicidins | 1 | 2025 | 10 | 0.060 |
Why?
|
| Bruch Membrane | 1 | 2025 | 9 | 0.060 |
Why?
|
| Macaca mulatta | 2 | 2014 | 251 | 0.060 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2025 | 53 | 0.060 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2025 | 35 | 0.060 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2025 | 58 | 0.060 |
Why?
|
| Host-Pathogen Interactions | 2 | 2016 | 262 | 0.060 |
Why?
|
| Half-Life | 1 | 2024 | 80 | 0.050 |
Why?
|
| Gram-Positive Bacteria | 1 | 2024 | 36 | 0.050 |
Why?
|
| Gram-Negative Bacteria | 1 | 2024 | 57 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2014 | 5651 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2024 | 144 | 0.050 |
Why?
|
| Mutation | 1 | 2011 | 2607 | 0.050 |
Why?
|
| Cell Division | 1 | 2023 | 449 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2025 | 2107 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 74 | 0.040 |
Why?
|
| Protein Domains | 1 | 2019 | 147 | 0.040 |
Why?
|
| Papio | 1 | 2008 | 14 | 0.040 |
Why?
|
| Complement C3 Convertase, Alternative Pathway | 1 | 2017 | 5 | 0.040 |
Why?
|
| Oligosaccharides | 1 | 2008 | 54 | 0.040 |
Why?
|
| Amino Acid Motifs | 1 | 2008 | 153 | 0.030 |
Why?
|
| Complement C3 | 1 | 2017 | 59 | 0.030 |
Why?
|
| Neisseria | 1 | 2016 | 4 | 0.030 |
Why?
|
| Molecular Mimicry | 1 | 2016 | 31 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2008 | 410 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 5448 | 0.030 |
Why?
|
| Male | 3 | 2025 | 29814 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 191 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2018 | 705 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2017 | 2152 | 0.030 |
Why?
|
| Rabbits | 1 | 2013 | 332 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2013 | 319 | 0.020 |
Why?
|
| Serum Bactericidal Antibody Assay | 1 | 2012 | 6 | 0.020 |
Why?
|
| Vaccines, Conjugate | 1 | 2011 | 18 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2011 | 99 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2011 | 290 | 0.020 |
Why?
|
| Lung | 1 | 2016 | 953 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2010 | 189 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 701 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 229 | 0.020 |
Why?
|
| Immunity | 1 | 2010 | 107 | 0.020 |
Why?
|
| Aged | 1 | 2025 | 14390 | 0.020 |
Why?
|
| Middle Aged | 1 | 2025 | 17549 | 0.020 |
Why?
|
| Rats | 1 | 2011 | 1977 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2011 | 796 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 1617 | 0.010 |
Why?
|
| Adult | 1 | 2011 | 16782 | 0.010 |
Why?
|